What are the indications, recommended dosing, contraindications, and common adverse effects of duloxetine?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 19, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Duloxetine: Clinical Overview

Duloxetine is a serotonin-norepinephrine reuptake inhibitor (SNRI) approved for major depressive disorder, generalized anxiety disorder, diabetic peripheral neuropathic pain, fibromyalgia, and chronic musculoskeletal pain, with a recommended starting dose of 30 mg once daily for one week, then 60 mg once daily for most indications.

Approved Indications

Duloxetine is FDA-approved for:

  • Major depressive disorder (MDD) in adults 1
  • Generalized anxiety disorder (GAD) in adults and children ≥7 years 1
  • Diabetic peripheral neuropathic pain (DPNP) 2
  • Fibromyalgia 1
  • Chronic musculoskeletal pain 1

Note: Duloxetine is NOT approved for MDD in pediatric patients 1

Recommended Dosing

Adults

For most indications, start at 30 mg once daily for 1 week, then increase to 60 mg once daily 2. This titration strategy significantly reduces nausea, the most common adverse effect 2.

  • Standard dose: 60 mg once daily (as effective as 60 mg twice daily) 2
  • Maximum dose: 120 mg/day (60 mg twice daily) 2, 1
  • Important: Doses above 60 mg/day for neuropathic pain are not recommended—they provide no additional efficacy and increase adverse effects 3
  • Duration of adequate trial: 4 weeks at target dose 2

Pediatric Patients (GAD only, ages 7-17)

  • Start: 30 mg once daily
  • Increase to 60 mg once daily after 1 week
  • Maximum: 120 mg/day 1

Administration

  • Swallow capsules whole—do not chew, crush, open, or sprinkle contents 1
  • May take with or without food 1
  • If switching from another antidepressant, taper the initial medication first to avoid adverse effects 1

Contraindications and Precautions

Absolute Contraindications

  • Concurrent use with MAOIs (allow 14-day washout) 1
  • Concurrent use with thioridazine (risk of serious arrhythmias) 1
  • Uncontrolled narrow-angle glaucoma 1

Use with Extreme Caution or Avoid

  • Hepatic impairment: Avoid in any hepatic disease 1, 3
  • Severe renal impairment: Avoid if CrCl <30 mL/min 1, 3
  • Heavy alcohol use: Risk of severe liver injury 1
  • Cardiac disease: Monitor blood pressure; venlafaxine may be preferred over duloxetine for cardiac patients 2

Drug Interactions

  • CYP1A2 inhibitors (ciprofloxacin, enoxacin): Avoid combination 1, 4
  • CYP2D6 substrates: Duloxetine inhibits CYP2D6; monitor drugs metabolized by this pathway 4
  • Serotonergic drugs (SSRIs, SNRIs, triptans, tramadol, fentanyl): Risk of serotonin syndrome 1
  • Anticoagulants/NSAIDs: Increased bleeding risk 1

Common Adverse Effects

Most Common (≥5% and twice placebo rate)

Adults:

  • Nausea (most common reason for discontinuation) 5, 2
  • Dry mouth
  • Somnolence/fatigue
  • Constipation
  • Decreased appetite
  • Increased sweating
  • Dizziness 1

Pediatric patients (additional concerns):

  • Decreased weight (14% vs 6% placebo) 1
  • Vomiting
  • Abdominal pain
  • Monitor height and weight regularly in children 1

Serious Adverse Effects to Monitor

  1. Suicidality: Black box warning—monitor closely, especially in patients <25 years and during initial treatment or dose changes 1

  2. Hepatotoxicity: Watch for jaundice, dark urine, right upper quadrant pain, elevated liver enzymes 1

  3. Blood pressure changes:

    • Can increase blood pressure
    • Can cause orthostatic hypotension and falls (especially elderly)
    • Monitor BP before and during treatment 1
  4. Serotonin syndrome: Agitation, hallucinations, tachycardia, hyperthermia, hyperreflexia, muscle rigidity—life-threatening 1

  5. Abnormal bleeding: Increased risk, especially with concurrent anticoagulants/NSAIDs 1

  6. Hyponatremia: Particularly in elderly patients 1

  7. Urinary retention: Decreased urine flow or inability to void 1

  8. Angle-closure glaucoma: Eye pain, vision changes, eye swelling/redness 1

  9. Seizures: Risk increases with abrupt discontinuation 1

Discontinuation Syndrome

Never stop abruptly—taper gradually to avoid withdrawal symptoms including: dizziness, headache, nausea, irritability, insomnia, electric shock-like sensations, anxiety 1

Clinical Pearls

  • Neuropathic pain: Duloxetine is a first-line agent for diabetic peripheral neuropathy with consistent efficacy 2. Pain relief can occur within one week at 60 mg/day 6
  • Comorbid conditions: Excellent choice when depression/anxiety coexists with chronic pain, fibromyalgia, or diabetic neuropathy 3
  • Glycemic control: No clinically significant effect on blood glucose in diabetic patients 3
  • Cardiovascular safety: Unlike venlafaxine, duloxetine does not produce clinically important ECG changes or significant blood pressure increases in most patients 2
  • Combination therapy: If inadequate response at 60 mg/day for neuropathic pain, add gabapentin or pregabalin rather than increasing duloxetine dose 3
  • Aminotransferase monitoring: Not routinely necessary per recent reviews 2

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.